http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9924053-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a819eda0adf22936a52362eeebb9fb4 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-043 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-04 |
| filingDate | 1998-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b942865537e17157a55012d5bd32e147 |
| publicationDate | 1999-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-9924053-A1 |
| titleOfInvention | Enhanced opening of abnormal brain tissue capillaries |
| abstract | Improved compositions and methods for increasing permeability of abnormal brain tissue to pharmaceutical agents. Cyclic GMP specific phosphodiesterase inhibitors are combined with bradykinin or a bradykinin analog to provide enhanced permeability of brain capillaries which is limited to abnormal brain tissue. Neuropharmaceutical and neurodiagnostic agents introduced into the bloodstream are directed selectively to the abnormal brain tissue. The pharmaceutical preparation composed of bradykinin or a bradykinin analog and a cyclic GMP specific phosphodiesterase inhibitor may be administered either intravenously or directly into the carotid artery. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1850852-A4 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1850852-A2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6235782-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0027391-A1 |
| priorityDate | 1997-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 96.